PCM
PRME icon

Polymer Capital Management’s Prime Medicine PRME Stock Holding History

Polymer Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,317
Closed -$35.9K – 906
2026
Q1 		$35.9K Sell
10,317
-25,664
-71% -$97.7K ﹤0.01% 801
2025
Q4 		$125K Buy
35,981
+15,190
+73% +$67.6K 0.01% 720
2025
Q3 		$115K Buy
+20,791
New +$84.5K 0.01% 724

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Polymer Capital Management's PRME Position: Q2 2026 in Review

Polymer Capital Management sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 10,317 shares — an estimated $35.9K sold.

Polymer Capital Management first reported a position in PRME in Q3 2025 and held it in 3 quarters. The position peaked at $125K in Q4 2025. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Polymer Capital Management reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • Polymer Capital Management sold 10,317 Prime Medicine shares in Q2 2026, an estimated $35.9K.
  • Polymer Capital Management first reported a position in Prime Medicine in Q3 2025 and held it in 3 quarters.
  • Polymer Capital Management's Prime Medicine position peaked at $125K in Q4 2025.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Polymer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.